

## A multi-site pilot study of the deployment of cholera rapid diagnostic tests in the Democratic Republic of the Congo

Wendelin Moser<sup>1,2</sup>, Anaïs Broban<sup>1,2</sup>, Placide Okitayemba Welo<sup>3</sup>, Daniel Mukadi<sup>4</sup>, Sibylle Gerstl<sup>1,2</sup>, Emily Briskin<sup>1,2</sup>, Nana Mimbu<sup>1,2</sup>, Isabel Amoros Quiles<sup>2</sup>, Christopher Mambula<sup>2</sup>, Ruwan Ratnayake<sup>5</sup>, Andrew Azman<sup>6,7</sup>, Flavio Finger<sup>1,2</sup>

<sup>1</sup>Epicentre Paris, Paris, France, <sup>2</sup> Médecins Sans Frontières, Paris, France, <sup>3</sup> National Program for the Elimination of Cholera and the Control of Other Diarrheal Diseases, Kinshasa, DR Congo, <sup>4</sup> National Institute for Biomedical Research, Goma, DR Congo, <sup>5</sup> London School of Hygiene & Tropical Medicine, London, UK, <sup>6</sup> Médecins Sans Frontières, Geneva, Switzerland, <sup>7</sup> Johns Hopkins University, Maryland, USA



## Introducing RDTs to overcome limitations of the cholera surveillance system

## Laboratory confirmation constraints (culture and/or PCR)

→due to logistical constraints and laboratory capacity

### Low specificity of the case definition

#### →Inclusion of other diarrheal diseases

#### Short shelf life, supply, cost

 $\rightarrow$  No need to test everyone?

#### Low specificity of RDT

→ 80% (74%-84%)

Number of suspected chole tested by RDT	ra cases	Number of suspected cholera cases tested positive by RDT	Interpretation
Among 3 to 7 suspected case	s tested	At least 3 RDT+	
Among 8 to 10 suspected cases tested Among 11 to 14 suspected cases tested Among 15 to 17 suspected cases tested		At least 4 RDT+	Probable cholera
		At least 5 RDT+	outbreak
		At least 6 RDT+	detected
Among 18 to 21 suspected cases tested		At least 7 RDT+	

#### Estimating cholera incidence using RDTs

 $\rightarrow$  Real time outbreak monitoring e.g. for vaccination decision taking

## RDT sampling scheme change after GTFCC threshold reached

ightarrow Testing first 3 suspected cases per day per health facility

#### **Enrichment with Alkaline Peptone Water?**





#### **Primary objective**

Compare the incidence based on different RDT sampling scheme to the true clinical incidence of cholera.

#### Secondary objectives

**Evaluate the practical use of RDTs for surveillance:** compliance, timeliness, reporting, consumption, supply, cost

Evaluate the performance of different cholera RDTs with and without enrichment



#### **Secondary objectives**

Implement a <u>specific predefined sampling scheme</u> in a setting with minimal study team support and evaluate compliance to application, timeliness of reporting, consumption, supply, and cost.



### Strategies in DRC: ZS Mulongo and ZS Mukanga

- 1. Strategy: Storage of RDTs
- 2. Strategy: RDT testing

#### **ZS Mulongo**



#### **ZS Mukanga**





## Replication: DRC site C strategy - in the province Maradi, Niger

- 1. Strategy: Storage of RDTs
- 2. Strategy: RDT testing

#### **DS Madarounfa**







### **RESULTS - Overview**





RDT missing	RDT negative	RDT positive
-------------	--------------	--------------

	Site A	Site B	Site C
Study start (2023)	Week 20	Week 26	Week 25
Nb participants enrolled	8'841	412	925
Crystal VC 01/0139	5'499	374	802
Positivity	47.1%	80.2%	70.1%

### Incidence based on RDT sampling schemes

#### Objective

Compare incidences based on :

- Gold standard (qPCR and/or culture) versus different RDT sampling schemes
- High (Site A) versus low-medium (Site B) incidence settings

#### **Sampling Schemes Examples**

- 1. First arriving suspect cases per day (First: 1, 2, 3 a day)
- First arriving suspect cases stratified by age group (< 5 and ≥5 years) and by day (First: 1, 2, 3, 4, 5 a day)
- 3. First arriving suspect cases by week (first 5, 10, 15, 20)
- 4. Etc....

## Identifying sampling schemes

(Data collection in progress [data analysed up to the 29.04.2024]: Preliminary and Incomplete Results)



# Testing of the GTFCC probable outbreak threshold in a real-world setting



(Data collection in progress [data analysed up to the 29.04.2024]: Preliminary and Incomplete Results)



## Testing of RDT sampling schemes in a real-world setting

(Data collection in progress [data analysed up to the 29.04.2024]: Preliminary and Incomplete Results)



117

148

Mukanga

Mulongo

98

144

84%

97%

15

1

13%

0%

2

0

## **RDT performance**



(Data collection in progress [data analysed up to the 29.04.2024]: Preliminary and Incomplete Results)

#### No qPCR results yet avaliable

#### Gold standard: culture



## **RDT** application observations

	Average time	SOP step compliance
Stool collection	2:44 min	83% (4 steps)
RDT preparation	5:05 min	88% (10 steps)
Reading and recording	4:50 min	72% (8 steps)
Total	12:39* min	

\*Excluding 15-30 minutes until result reading

#### Main challenges

#### Result interpretation





## Conclusion

- Over **10,000 suspected cases were included** in DRC (up to April 29, 2024), with the study planned for continuation until the end of June 2024.
- Comparing the performance to the RDTs (with and without enrichment) showed **highest sensitivity for the Crystal VC 01/0139**.
- Preliminary analysis, including only three sampling schemes (with further comparisons underway), has revealed a **convergence in incidence rates** between **exhaustive testing** and the examination of solely the **first three suspect cases** daily per structure.
- Applying a sampling scheme (e.g. RDT testing of first 3 patients/day/structure) might allow to conserve few RDTs in low-incidence settings, however, in highincidence settings almost two-third of the RDTs can be saved.
- In a health zone with minimal study team implication, a **probable outbreak was** correctly detected using the GTFCC probable outbreak threshold.
- The change in sampling scheme after reaching the GTFCC threshold showed to be challenging. More training and supervision likely necessary.

## Merci à tout le monde

#### Epicentre

**Flavio Finger** Anais Broban **Emily Briskin** Nana Mimbu Francois Kabasela Innocent Mugisho Joseph Kasareka Patient Kamavu **Guy Walombe** Sibylle Gerstl Manal Shamseldin Pierre Kasongo Jonas Kamono Begge Kayembe

#### PNECHOL

Dr Placide WELO OKITAYEMBA

### **DPS/BCZ/CTC** All MCZs

All CTC nurses

#### Labo

Dr Daniel Mukadi DR Jaques Muzinga











### Mode of data transmission

Notifiable diseases (aggregated weekly cholera cases)

